Biogen: Aducanumab Questions Linger After CTAD, but Trading Opportunities Exist
thenonconsensus.substack.com
Summary On Thursday, Biogen presented additional aducanumab data at CTAD that answered some questions, and raised others Bulls believe the totality of the data, including the first positive pivotal trial in Alzheimer’s, is supportive of approval Bears believe the data is too confounding to receive approval
Biogen: Aducanumab Questions Linger After CTAD, but Trading Opportunities Exist
Biogen: Aducanumab Questions Linger After…
Biogen: Aducanumab Questions Linger After CTAD, but Trading Opportunities Exist
Summary On Thursday, Biogen presented additional aducanumab data at CTAD that answered some questions, and raised others Bulls believe the totality of the data, including the first positive pivotal trial in Alzheimer’s, is supportive of approval Bears believe the data is too confounding to receive approval